By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Smiths Detection and Novartis Diagnostics have signed a license and collaboration agreement to develop and commercialize Smiths Detection's Bio-Seeq PCR-based instrument and infectious disease diagnostic tests.

Smiths will develop and enhance the Bio-Seeq platform for use in a range of point-of-care diagnostic tests that Novartis Diagnostics will then move through clinical trials, regulatory affairs, and sales and marketing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.